Sort
82,697 grants matching “vaccine development”
Immune Deficient Mosquitoes for Improved Malaria Sporozoite Vaccine Manufacture
$998,817Peter F. Billingsley · Sanaria, Inc. · R44 · FY2017 · AI
Liquid Immunotherapeutic Fiducial Eluter (LIFE) Gel for Cervical Cancer
$998,781Adam Shilling · Nanocan Therapeutics Corporation · R42 · FY2025 · CA
Expanding the Market and Success Rates for Myeloablative Cancer Treatments Using PUL-042, an Innate Immune Stimulant
$998,771Brenton Scott · Pulmotect, Inc · R44 · FY2016 · HL
Expanding the Market and Success Rates for Myeloablative Cancer Treatments Using PUL-042, an Innate Immune Stimulant
$998,771Brenton Scott · Pulmotect, Inc · R44 · FY2017 · HL
Pre-Clinical Development of a Intranasal Bivalent gD2/gB2 HSV-2 Mucosal Vaccine
$998,684Ali I. Fattom · Bluewillow Biologics, Inc. · R44 · FY2020 · AI
Microneedle Delivery of Zanamivir for the Treatment of Influenza Infections
$998,663Elke Lipka · Tsrl, Inc. · R44 · FY2024 · AI
A Novel Probiotic for the Treatment of Sjogren's Syndrome
$998,658Gary Fanger · Rise Therapeutics, Llc · SB1 · FY2021 · DE
Microneedle Delivery of Zanamivir for Treatment of Influenza
$998,654Elke Lipka · Tsrl, Inc. · R44 · FY2019 · AI
Core 1: Nonhuman Primate Core
$998,573Sallie R. Permar · Duke University · P01 · FY2019 · AI
COBRE Phase III: Transitional Center for Research on Processes in Evolution
$998,552Larry J Forney · University Of Idaho · P30 · FY2014 · GM
Optimization of a Therapeutic HIVSIV Multi-Antigen DNA Vaccine
$998,486Kenneth C Bagley · Profectus Biosciences, Inc. · R44 · FY2015 · AI
DEVELOPMENT OF A NOVEL MULTIENVELOPE AIDS VACCINE
$998,405St. Jude Children'S Research Hospital · P01 · FY2004 · AI
Induction of an Antitumor Immune Response in Patients with Melanoma
$998,246Patrick Hwu · University Of Tx Md Anderson Can Ctr · P50 · FY2014 · CA
Chikungunya Recombinant Subunit Vaccine
$998,229David E. Clements · Hawaii Biotech, Inc. · R44 · FY2025 · AI
An epitope-focused nanoparticle vaccine for anthrax
$998,145David C Whitacre · Vlp Biotech, Inc. · R44 · FY2020 · AI
GelVac Stable, Dry-Powder Nasal Recombinant VLP-Based Bivalent Norovirus Vaccine
$997,966James Forrest Kirk · Nanotherapeutics, Inc. · R44 · FY2015 · AI
Quantitative mapping of dynamic epigenetic states in rare and stimulated immune cells
$997,966Michael-Christopher Keogh · Epicypher, Inc. · R44 · FY2024 · AI
Supported employment to create a community culture of SARS-CoV-2 rapid testing among people who inject drugs: PeerConnect2Test
$997,902Camille C Cioffi · University Of Oregon · U01 · FY2023 · DA
Development of Broad Spectrum Host Oriented Therapeutic Antibodies against Influe
$997,899Wu-Bo Li · Functional Genetics, Inc. · R44 · FY2012 · AI
Integrin activator-adjuvanted DNA vaccine against Trypanosoma cruzi infection
$997,867Upendra Marathi · 7 Hills Pharma, Llc · R44 · FY2023 · AI
Integrin activator-adjuvanted DNA vaccine against Trypanosoma cruzi infection
$997,867Upendra Marathi · 7 Hills Pharma, Llc · R44 · FY2024 · AI
GelVac Stable, Dry-Powder Nasal Recombinant VLP-Based Bivalent Norovirus Vaccine
$997,804James Forrest Kirk · Nanotherapeutics, Inc. · R44 · FY2014 · AI
Modeling the ecology of tissue-resident T cells
$997,716Andrew Yates · Columbia University Health Sciences · U01 · FY2022 · AI
Therapeutic Antibody for RSV IIB
$997,704Lawrence Michael Kauvar · Trellis Bioscience, Inc. · R44 · FY2021 · AI
SBIR Phase II: Design and production of a next generation vaccine to prevent COVID
$997,689Peter M Leonardi · Omnicyte, Llc · · FY2024 · TIP